Is There an Ethical Obligation to Disclose Controversial Risk? A Question From the ACCORD Trial

被引:7
作者
DeMarco, Joseph P. [1 ]
Ford, Paul J. [2 ]
Patton, Dana J. [2 ]
Stewart, Douglas O. [1 ]
机构
[1] Cleveland State Univ, Cleveland, OH 44115 USA
[2] Cleveland Clin, Cleveland, OH USA
关键词
biomedical research; institutional review board; professional ethics; research ethics; informed consent; CONSENT DOCUMENTS; TYPE-2;
D O I
10.1080/15265161.2014.889240
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
Researchers designing a clinical trial may be aware of disputed evidence of serious risks from previous studies. These researchers must decide whether and how to describe these risks in their model informed consent document. They have an ethical obligation to provide fully informed consent, but does this obligation include notice of controversial evidence? With ACCORD as an example, we describe a framework and criteria that make clear the conditions requiring inclusion of important controversial risks. The ACCORD model consent document did not include notice of prior trials with excess death. We develop and explain a new standard labeled risk in equipoise. We argue that our approach provides an optimal level of integrity to protect the informational needs of the reasonable volunteers who agree to participate in clinical trials. We suggest language to be used in a model consent document and the informed consent discussion when such controversial evidence exists.
引用
收藏
页码:4 / 10
页数:7
相关论文
共 27 条
  • [1] Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes
    Abraira, C
    Colwell, J
    Nuttall, F
    Sawin, CT
    Henderson, W
    Comstock, JP
    Emanuele, NV
    Levin, SR
    Pacold, I
    Lee, HS
    Silbert, CK
    Cxypoliski, R
    Vasquez, M
    Kernan, D
    Niewoehner, C
    Backes, M
    Bradley, M
    Bradley, M
    Crow, R
    Rubino, F
    Bushnell, D
    Pfeifer, M
    Service, FJ
    Howard, B
    Chew, E
    Hoogwerf, B
    Seigel, D
    Clark, CM
    Olefsky, JM
    Porte, D
    Sussman, KE
    Johnson, N
    Christine, B
    Tir, K
    Sather, M
    Day, P
    Morgan, N
    Deykin, D
    Gold, J
    Huang, P
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) : 181 - 188
  • [2] ACCORD Study Group, 2009, ACT CONTR CARD RISK
  • [3] [Anonymous], 1998, Wingspread statement on the precautionary principle
  • [4] [Anonymous], 1979, BELM REP
  • [5] [Anonymous], DIABETES S2
  • [6] [Anonymous], 1964, Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
  • [7] The length of consent documents in oncological trials is doubled in twenty years
    Berger, O.
    Gronberg, B. H.
    Sand, K.
    Kaasa, S.
    Loge, J. H.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (02) : 379 - 385
  • [8] BOUSSAGEON R, 2011, BRIT MED J, V343
  • [9] Secrets of the MMR scare The Lancet's two days to bury bad news
    Deer, Brian
    [J]. BRITISH MEDICAL JOURNAL, 2011, 342 : 200 - 204
  • [10] EQUIPOISE AND THE ETHICS OF CLINICAL RESEARCH
    FREEDMAN, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (03) : 141 - 145